ADHD PreSMA Response Inhibition Therapy
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
Study Type
Study Type
Enrollment (Estimated)
Enrollment
Phase
Phase
- Not Applicable
Contacts and Locations
Study Contact
Study Contact
- Name: Karlee Migneault, B.A.
- Phone Number: 513-803-5299
- Email: Karlee.Migneault@cchmc.org
Study Locations
-
-
Ohio
-
Cincinnati, Ohio, United States, 45229
- Recruiting
- Cincinnati Children's Hospital Medical Center
-
Contact:
- Karlee Migneault
- Phone Number: 513-803-5299
- Email: karlee.migneault@cchmc.org
-
Principal Investigator:
- Steve Wu, MD
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
- Child
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- ADHD diagnosis
- Ages 12-17 years
- Stimulant use is allowed but must be discontinued 24 hours prior to and during days of TMS visit
Exclusion Criteria:
- Medical conditions contraindicated or associated with altered TMS risk profile, including history of intracranial pathology, epilepsy or seizure disorders, traumatic brain injury, brain tumor, stroke, intellectual disability, cerebral palsy, neurodegenerative conditions, hearing impairment, metallic objects in the head or any other serious medical condition
- Presence of any implanted medical devices (e.g., ports, shunts, stimulators, cochlear implants)
- For biological females who are post-menarche, current pregnancy based on urine pregnancy test.
- Baseline problem of hearing impairment or chronic tinnitus
- Any clinically significant finding on brain MRI
- History of DSM-5 conduct disorder, major depressive disorder, bipolar disorder, obsessive compulsive disorder, anxiety disorder, psychotic disorder
- Non-stimulant medication(s) for ADHD (e.g., alpha2 adrenergic agonist, atomoxetine, tricyclics)
- Neuroleptic/antipsychotic medication(s)
- Inability to undergo MRI
- Active suicidality, history of suicidality, or high risk for suicide as assessed by a study physician
- Substance abuse or dependence within the past year, based on 1) separate screening process of asking parent/guardian and participant, and 2) positive urine drug screen. Exception will be made for positive urine drug screen due to prescribed ADHD medication
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Basic Science
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Double
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Active Comparator: Active repetitive TMS
|
In this study, ADHD children will receive two trains of intermittent theta burst stimulation.
Intermittent theta burst stimulation is a form of repetitive TMS.
Both iTBS trains will be active stimulation using the active TMS coil.
|
|
Sham Comparator: Sham repetitive TMS
|
In this study, ADHD children will receive two trains of intermittent theta burst stimulation.
Intermittent theta burst stimulation is a form of repetitive TMS.
The first iTBS train will be sham stimulation using the sham TMS coil.
The second iTBS train will be active stimulation using the active TMS coil.
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
TMS-based Short-Interval Intracortical Inhibition (SICI)
Time Frame: Immediately after each iTBS train
|
This is a measure of primary motor cortex inhibitory activity.
|
Immediately after each iTBS train
|
|
EEG-based beta activity
Time Frame: Immediately after each iTBS train
|
This is a measure of beta-band activity during performance of stop signal task.
|
Immediately after each iTBS train
|
|
TMS-based Cortical Silent Period (cSP)
Time Frame: Immediately after each iTBS train
|
This is a measure of primary motor cortex inhibitory activity.
|
Immediately after each iTBS train
|
|
EEG-based alpha activity
Time Frame: Immediately after each iTBS train
|
This is a measure of alpha-band activity during performance of stop signal task.
|
Immediately after each iTBS train
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Stop Signal Reaction Time
Time Frame: Immediately after each iTBS train
|
This is a measure calculated from the stop signal task.
This is an experimental measure of how well the participant can inhibit a motor action.
|
Immediately after each iTBS train
|
Collaborators and Investigators
Sponsor
Sponsor
Investigators
Investigators
- Principal Investigator: Steve W Wu, M.D., Children's Hospital Medical Center, Cincinnati
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Estimated)
Primary Completion
Study Completion (Estimated)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- CIN001 - ADHD PreSMART
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.